𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

✍ Scribed by Carmen D. Schweighofer; Matthias Ritgen; Barbara F. Eichhorst; Raymonde Busch; Wolfgang Abenhardt; Michael Kneba; Michael Hallek; Clemens-Martin Wendtner


Book ID
108676006
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
112 KB
Volume
144
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.